
Grace Therapeutics, Inc.
100
Recent developments include Q2 2026 financial results showing a widened loss without prior-year warrant gain, advancement of GTx-104 development plans, and preparations to resubmit the NDA for GTx-104 following the FDA’s Complete Response Letter.
- Grace Therapeutics reported a net loss of $2.13 million for Q2 2027 ended September 30, 2026, with no prior-year warrant gain impacting results, and provided updates on advancing GTx-104 development plans [N1].
- The company announced financial results for the three months ended September 30, 2026, highlighting steady progress and ongoing efforts related to GTx-104 [N2].
- Grace recorded a net loss of $7 million for fiscal year 2026 and disclosed plans to resubmit the NDA for GTx-104 in subarachnoid hemorrhages following the FDA’s Complete Response Letter [N3].
- The company completed a private placement raising approximately $9.2 million net proceeds in August 2026 to support GTx-104 development [N4].
Grace Therapeutics, Inc. develops proprietary formulations of approved pharmaceutical compounds targeting rare and orphan diseases to improve clinical outcomes. Its lead product candidate, GTx-104, is a novel injectable formulation of nimodipine designed for intravenous infusion in patients with aneurysmal subarachnoid hemorrhage (aSAH), addressing limitations of oral nimodipine such as poor solubility, hypotension, and variable bioavailability. The company’s pipeline also included GTx-102 for ataxia-telangiectasia and GTx-101 for postherpetic neuralgia, but internal development funding for these was discontinued in June 2026. Grace’s management team has expertise in drug development, regulatory affairs, and commercialization. The company’s NDA for GTx-104 was accepted by the FDA but received a Complete Response Letter in April 2026 citing manufacturing and non-clinical data issues, with plans for resubmission underway. Financially, as of September 30, 2026, Grace held $21.3 million in cash and equivalents, reported a net loss of $2.13 million for the quarter, and maintains strong liquidity ratios. The company completed a $10 million private placement in August 2026 to support ongoing development.
Grace Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug delivery formulations for rare and orphan diseases, primarily advancing its lead candidate GTx-104, an injectable nimodipine formulation for aneurysmal subarachnoid hemorrhage (aSAH). The company reported a net loss of $2.13 million for Q2 2027 ending September 30, 2026, with cash and equivalents of $21.3 million and strong liquidity ratios. The FDA issued a Complete Response Letter for GTx-104's NDA in April 2026 citing manufacturing and non-clinical data issues but no safety or efficacy concerns, prompting plans for NDA resubmission. Grace completed a private placement in August 2026 raising net proceeds of $9.2 million and continues to focus its resources on GTx-104 development following strategic realignment and discontinuation of other pipeline candidates. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Grace Therapeutics’ lead candidate GTx-104 demonstrated positive Phase 3 trial results with reduced hypotension and favorable clinical outcomes compared to oral nimodipine, supporting its potential to address unmet needs in aSAH treatment. The company’s proprietary injectable formulation technology and strong patent portfolio could provide differentiation and market exclusivity. The orphan drug designation and associated regulatory incentives may reduce development costs and support market entry. Recent private placement funding enhances financial resources to advance GTx-104 development and regulatory interactions. The management team’s expertise and strategic focus on GTx-104 streamline operations and resource allocation.
The FDA issued a Complete Response Letter for GTx-104’s NDA citing manufacturing and non-clinical data deficiencies, delaying potential approval and commercialization. The company discontinued internal development of other pipeline candidates, narrowing its product focus and increasing reliance on GTx-104’s success. Operating losses and negative cash flows continue, with net losses reported and limited liquidity runway despite recent financing. The orphan drug market is competitive and subject to regulatory and reimbursement uncertainties. Clinical trial outcomes and regulatory approvals remain uncertain, and manufacturing challenges could impact timelines and costs.
Grace Therapeutics’ moat is based on its proprietary drug delivery technology and formulation expertise applied to approved drugs for rare diseases, supported by a portfolio of over 79 patents worldwide. Its lead candidate, GTx-104, leverages novel nanoparticle technology to overcome solubility and bioavailability challenges of oral nimodipine, potentially offering improved safety and efficacy in aSAH treatment. The orphan drug designation and potential orphan drug exclusivity provide regulatory and market advantages. The company’s focused pipeline and specialized management team with domain expertise in neurology and drug development further support its competitive positioning in a niche market with significant unmet medical needs.
• Regulatory Risk: The FDA’s Complete Response Letter for GTx-104 highlights risks related to manufacturing and non-clinical data requirements that must be addressed for NDA resubmission and approval.
• Financial Risk: The company has incurred operating losses and negative cash flows, with limited cash reserves that require careful management and potential additional financing.
• Pipeline Concentration Risk: Discontinuation of internal development for GTx-102 and GTx-101 increases reliance on the success of GTx-104 for future growth and value creation.
• Market Adoption Risk: Adoption of GTx-104 depends on acceptance by hospitals and physicians, reimbursement policies, and competitive alternatives in the aSAH treatment landscape.
Business trends: Focus on advancing GTx-104 injectable nimodipine for aSAH with orphan drug incentives and clinical data supporting improved safety and efficacy.
Execution milestones: Address FDA Complete Response Letter issues, resubmit NDA, and manage financial resources including recent private placement proceeds.
Key risks: Regulatory approval uncertainties, financial sustainability amid operating losses, and reliance on a single lead product candidate.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Grace Therapeutics, Inc. focuses on developing and commercializing products for rare and orphan diseases using novel drug delivery technologies, applying proprietary formulations to approved pharmaceutical compounds to improve efficacy and patient outcomes [S1].
- The company has three clinical-stage drug candidates: GTx-104, GTx-102, and GTx-101, supported by over 79 granted and pending patents worldwide [S1].
- GTx-104 is a novel injectable formulation of nimodipine for intravenous infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients, designed to overcome limitations of oral nimodipine such as poor solubility, hypotension, and variable bioavailability [S1].
- GTx-104 uses nanoparticle technology with non-ionic surfactant micelles to solubilize nimodipine, is stable at room temperature, and has been administered to over 200 patients and healthy volunteers with good tolerability and lower pharmacokinetic variability compared to oral capsules [S1].
- The Phase 3 STRIVE-ON trial for GTx-104 met its primary endpoint, showing a 19% reduction in clinically significant hypotension episodes compared to oral nimodipine, with favorable clinical and pharmacoeconomic outcomes [S1].
- The FDA accepted the NDA for GTx-104 in August 2025 with a PDUFA target date of April 23, 2026; however, in April 2026, the FDA issued a Complete Response Letter (CRL) citing CMC and non-clinical issues but no safety or efficacy concerns, leading to plans for NDA resubmission [S1][N6][N3].
- The company implemented a strategic realignment in May 2023, focusing on GTx-104 development and discontinuing internal funding for GTx-102 and GTx-101 as of June 2026, including impairment of related intangible assets [S1][S2].
- Financial snapshot as of September 30, 2026: cash and cash equivalents of $21.3 million, current assets of $21.96 million, current liabilities of $1.61 million, net loss of $2.13 million for the quarter, and basic and diluted EPS of -$0.11 [S2].
- Liquidity ratios as of September 30, 2026: current ratio of 13.61 and cash ratio of 19.27, indicating strong short-term liquidity [S2].
- The company completed a private placement in August 2026, raising net proceeds of approximately $9.2 million [S2][N4].
- The company’s management team includes experienced professionals in drug formulation, regulatory affairs, and commercialization, including a neurosurgeon-scientist expert in aSAH [S1].
- The market opportunity for GTx-104 includes approximately 42,500 U.S. patients annually with aSAH, with additional cases in the EU and China, and market research indicates 80% likelihood of hospital adoption of an IV nimodipine formulation [S1].
- Recent news highlights include Q2 2026 financial results reporting widened loss without prior-year warrant gain and advancement of GTx-104 plans, and plans to resubmit NDA for GTx-104 following FDA CRL [N1][N2][N3].
Generated 2026-11-15
- S1 | 2026-06-18 | 10-K
- S2 | 2026-11-12 | 10-Q
- N1 | 2026-11-13 | www.nasdaq.com | Grace Therapeutics Q2 Loss Widens Without Prior-Year Warrant Gain; Advances GTx-104 Plans | https://www.nasdaq.com/articles/grace-therapeutics-q2-loss-widens-without-prior-year-warrant-gain-advances-gtx-104-plans
- N2 | 2026-11-13 | www.nasdaq.com | Grace Therapeutics, Inc. Reports Financial Results for the Three Months Ended September 30, 2026 and Provides GTx-104 Update | https://www.nasdaq.com/articles/grace-therapeutics-inc-reports-financial-results-three-months-ended-september-30-2026-and
- N3 | 2026-06-22 | www.nasdaq.com | Grace Records Net Loss Of $7 Mln In FY26; To Resubmit NDA For GTx-104 In Subarachnoid Hemorrhages | https://www.nasdaq.com/articles/grace-records-net-loss-7-mln-fy26-resubmit-nda-gtx-104-subarachnoid-hemorrhages
- N4 | 2026-02-12 | www.nasdaq.com | Grace Therapeutics Reports Steady Progress and Financials | https://www.nasdaq.com/articles/grace-therapeutics-reports-steady-progress-and-financials
- N5 | 2025-11-04 | www.nasdaq.com | Biotech Earnings Spark After-Hours Surge: TCMD, BDSX, EXAS Lead The Charge | https://www.nasdaq.com/articles/biotech-earnings-spark-after-hours-surge-tcmd-bdsx-exas-lead-charge
- N6 | 2025-08-27 | www.nasdaq.com | Grace Therapeutics: FDA To Review NDA For GTx-104 | https://www.nasdaq.com/articles/grace-therapeutics-fda-review-nda-gtx-104
- N7 | 2025-06-22 | www.nasdaq.com | GRACE THERAPEUTICS Earnings Preview: Recent $GRCE Insider Trading, Hedge Fund Activity, and More | https://www.nasdaq.com/articles/grace-therapeutics-earnings-preview-recent-grce-insider-trading-hedge-fund-activity-and
- N8 | 2025-06-13 | www.nasdaq.com | Grace Therapeutics CEO Prashant Kohli to Attend BIO 2025 International Conference in Boston | https://www.nasdaq.com/articles/grace-therapeutics-ceo-prashant-kohli-attend-bio-2025-international-conference-boston
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


